Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

With skin cancer on the rise across the UK, Boots is expanding dermatology training for its in-store pharmacists. Matt Nixson tried out its mole-scanning service ...

Castle Biosciences and SciBase join forces to create a predictive test for atopic dermatitis flare-ups. Read more here.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

Merck’s Animal Health division just fetched a major win as the EU's veterinary committee gave a tail-wagging thumbs-up to ...

ShareA new study led by researchers in the United Kingdom (UK) indicates that certain environmental exposures may affect a child’s risk of developing atopic eczema, a condition characterised by dry, ...